Short answer
ABEONA THERAPEUTICS INC. (ABEO) filed its Q2 2026 10-Q quarterly report on Aug 13, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $11M with net income of −$20M.
Q2 2026 key financials · XBRL
- Revenue
- $11M
- +30.5% QoQ
- Net income
- −$20M
- −118.6% YoY · −18.2% QoQ
- Operating margin
- -120.0%
- EPS (diluted)
- −$0.36
- −121.1% YoY · −20.0% QoQ
Source: XBRL data from the ABEONA THERAPEUTICS INC. (ABEO) Q2 2026 10-Q on SEC EDGAR. USD.
ABEONA THERAPEUTICS INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $11.4M, up $11.0M YoY, driven by ZEVASKYN product revenue
- ZEVASKYN best-performing line at $11.4M revenue; license revenue declined to $0 from $0.4M
- Operating loss $13.7M vs $22.8M YoY; operating margin -120.0% vs -5,698.0%
- Cash resources $146.8M at June 30, 2026; six-month operating cash outflow $37.3M
- Outlook: cash sufficient for at least 12 months, but additional funding may be needed; losses expected for several years
Risk Factors
- July 2026 cellular identity test out of specification blocked commercial release of one ZEVASKYN batch
- FDA-authorized single-patient IND release, while commercial authorization remains unavailable
- FDA specification-revision acceptance uncertain, creating regulatory compliance risk
- Autologous biopsy viability and cell proliferation delays may require repeat manufacturing
- August 2025 false-positive sterility assay caused manufacturing rejection and delayed launch
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ABEONA THERAPEUTICS INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.